Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients

• DOI: 10.1016/j.jchf.2024.12.004
• Publication Date: 2025-03-12T18:52:42Z
• Authors: Patric Karlström; Aldina Pivodic; Michael Fu

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown improved symptomatic relieving and functional capacity in patients with heart failure (HF) preserved ejection fraction obesity. The purpose of this study was to evaluate the effect GLP-1RA on outcome HF. A retrospective analysis performed based Swedish HF Registry since 2007 among a body mass index (BMI) >25 kg/m2 assess whether treatment associated reduced mortality In overall cohort, 34,247 were not treated GLP-1RA, 808 were. 96.3% had diabetes mellitus. Treatment showed statistically significant association all-cause (adjusted HR [aHR]: 0.75 [95% CI: 0.60-0.94]; P = 0.013) cardiovascular (CV) (aHR: 0.52 0.35-0.77]; 0.0010) compared those receiving within 2 years after registration. 1:1 propensity score matched there no between 0.79 0.59-1.06]; 0.11), but CV 0.53 0.32-0.87]; 0.012). GLP-1RA-associated risk reduction death more pronounced BMI >30 appears be greater individuals an ≤40% >40%. This nationwide real-world shows that who received mortality, which is particularly overweight obese fraction.